Arialys Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $14M

  • Investors
  • 6

Arialys Therapeutics General Information

Description

Operator of a clinical-stage biotechnology company intended to pioneer new precision medicines for autoimmune neuropsychiatric diseases. The company specializes in neuroscience and characterizes the nature and prevalence of pathogenic auto-antibody activity in the central nervous system and converged network services, enabling clients to access advanced breakthrough therapies for a variety of central nervous system disorders and to treat neuropsychiatric disorders driven by autoimmune diseases

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 290
  • La Jolla, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 290
  • La Jolla, CA 92037
  • United States
+1 (858)

Arialys Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arialys Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 30-Jun-2025 $14M Completed Clinical Trials - Phase 1
1. Seed Round 12-Sep-2023 Completed Clinical Trials - General
To view Arialys Therapeutics’s complete valuation and funding history, request access »

Arialys Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Arialys Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Arialys Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company intended to pioneer new precision medicines for autoimmune neuropsych
Drug Discovery
La Jolla, CA
10 As of 2023

Raritan, NJ
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arialys Therapeutics Competitors (80)

One of Arialys Therapeutics’s 80 competitors is Johnson&Johnson Innovative Medicine, a Venture Capital-Backed company based in Raritan, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Johnson&Johnson Innovative Medicine Venture Capital-Backed Raritan, NJ
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
ORIC Pharmaceuticals Formerly VC-backed South San Francisco, CA
Astellas Pharma Corporation Tokyo, Japan
Bridge Medicines Venture Capital-Backed New York, NY
You’re viewing 5 of 80 competitors. Get the full list »

Arialys Therapeutics Patents

Arialys Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026232008-A1 Cd98 binding polypeptides and uses thereof Pending 02-May-2025
WO-2026073156-A1 Detection of autoantibodies against nr1 Pending 30-Sep-2024
WO-2026020040-A1 Methods of treating anti-nmdar antibody related disorders Pending 19-Jul-2024
AU-2024242885-A1 Detection of autoantibodies against nr1 Pending 30-Mar-2023
EP-4689655-A1 Detection of autoantibodies against nr1 Pending 30-Mar-2023 G01N33/564
To view Arialys Therapeutics’s complete patent history, request access »

Arialys Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arialys Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Real Estate Equities Real Estate Minority
Alexandria Venture Investments Venture Capital Minority
Avalon Bioventures Venture Capital Minority
Catalys Pacific Venture Capital Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Arialys Therapeutics FAQs

  • When was Arialys Therapeutics founded?

    Arialys Therapeutics was founded in 2021.

  • Where is Arialys Therapeutics headquartered?

    Arialys Therapeutics is headquartered in La Jolla, CA.

  • What is the size of Arialys Therapeutics?

    Arialys Therapeutics has 10 total employees.

  • What industry is Arialys Therapeutics in?

    Arialys Therapeutics’s primary industry is Drug Discovery.

  • Is Arialys Therapeutics a private or public company?

    Arialys Therapeutics is a Private company.

  • What is the current valuation of Arialys Therapeutics?

    The current valuation of Arialys Therapeutics is .

  • What is Arialys Therapeutics’s current revenue?

    The current revenue for Arialys Therapeutics is .

  • How much funding has Arialys Therapeutics raised over time?

    Arialys Therapeutics has raised $72M.

  • Who are Arialys Therapeutics’s investors?

    Alexandria Real Estate Equities, Alexandria Venture Investments, Avalon Bioventures, Catalys Pacific, and Johnson & Johnson JJDC are 5 of 6 investors who have invested in Arialys Therapeutics.

  • Who are Arialys Therapeutics’s competitors?

    Johnson&Johnson Innovative Medicine, Dicerna Pharmaceuticals, ORIC Pharmaceuticals, Astellas Pharma, and Bridge Medicines are some of the 80 competitors of Arialys Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process